Your session is about to expire
← Back to Search
APG-2575 Combinations for Multiple Myeloma
Study Summary
This trial is testing a new cancer drug, APG-2575, to see if it is safe and effective in patients with multiple myeloma who have relapsed or are refractory to other treatments. The study will start with two arms, both of which are independent.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have plasma cell leukemia or a similar condition.I have newly diagnosed multiple myeloma and have had minimal or no treatment.I have AL amyloidosis and haven't received systemic therapy or have it with multiple myeloma.I haven't had a stroke, brain bleed, or bleeding disorder in the last 6 months.I have a serious heart condition that is currently affecting me.I haven't had any cancer other than specific exceptions in the last year.I need treatment with a strong medication that affects liver enzymes.I have severe nerve damage not caused by AL amyloidosis.I have AL amyloidosis, have had treatment before, and my disease can be measured.I do not have any uncontrolled infections.I have MM, treated 1-4 times before, and my condition worsened quickly after the last treatment.I cannot swallow pills or have a condition that affects how my body absorbs nutrients.I have received cancer treatment within the last 2 weeks.I have had a stem cell transplant from a donor.I recently needed treatment for an infection.My liver and kidneys are working well.My blood counts are within a healthy range.You are expected to live for at least 6 more months.I am 18 years old or older.I have not received any live vaccines in the last 4 weeks.I have not had major surgery in the last 14 days.I plan to have a stem cell transplant before my disease worsens on this study.I am not able to become pregnant or I have a negative pregnancy test.I agree to use effective birth control methods.I can perform all my self-care activities and remain up and about more than 50% of my waking hours.I have not undergone plasmapheresis within the last 35 days.I still have side effects from my previous MM or AL amyloidosis treatment.I have not had BCL-2 therapy in the last 4 weeks.
- Group 1: APG-2575 +Pd or LD
- Group 2: APG-2575+LD
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you provide a synopsis of previous experiments involving APG2575 + DRd?
"At present, there are 757 active studies for APG2575 + DRd with 169 trials in the Phase 3 stage. While Joliet, Illinois is one of many locations conducting these trials, 26277 sites around the world have been enlisted to participate."
What is the scope of individuals receiving treatment in this trial?
"To reach the target of 108 qualified participants, Ascentage Pharma Group Inc., will be running this trial at multiple sites such as Mayo Clinic in Jacksonville and Cleveland Clinic Hosptials in Ohio."
Is this study currently open to new participants?
"Affirmative. According to clinicaltrials.gov, this trial is actively seeking suitable candidates and was first published on December 23rd 2021. The most recent edit was made on February 28th 2022, with 108 volunteers needed from 3 different locations."
Is it possible for me to participate in this clinical trial?
"Applicants to this trial need to have a diagnosis of amyloidosis and be between 18 and 99 years old. The capacity for the study is 108 participants."
Does this clinical trial allow adults over the age of thirty to participate?
"This medical trial requires applicants to be between 18 and 99 years of age. It should also be noted that there are 124 clinical trials designed for those under the legal threshold, as well as 1560 studies catered towards elderly individuals."
What clinical conditions does the combination of APG2575 and DRd typically address?
"APG2575 + DRd is frequently prescribed for ophthalmia, sympathetic and can be used to treat a range of issues such as at least two previous systemic chemotherapy regimens, branch retinal vein occlusion, macular edema."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger